Celecoxib is a nonsteroidal anti-inflammatory drug used to reduce pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis and menstrual pain. To enhance its effectiveness and reduce the likelihood of side effects, it is essential to create drug delivery systems designed for better controlled release. We herein report the synthesis of [Cu3(btc)2] using the solvent-based method and characterized using BET, CHN, FT-IR, PXRD, SEM, TEM & TGA. [Cu3(btc)2] commonly referred to as HKUST-1/MOF-199 is among the first stable MOFs identified, boasting an exceptionally high surface area. After characterization, the synthesized [Cu3(btc)2] was modified by introducing ED into the framworks to form [Cu3(btc)2]-ED which was characterized by BET, EDX, FT-IR, PXRD, SEM, TEM and TGA. The two porous Cu-MOFs prepared in this study were used for storage and stable delivery of Celecoxib for the first time. The storage capacities of [Cu3(btc)2] and [Cu3(btc)2]-ED were 680.15 mg/g and 504.22 mg/g respectively, which also demonstrates effective and controlled drug delivery properties. The results indicate that the storage capacity of [Cu3(btc)2] is higher than that of [Cu3(btc)2]-ED, which could be attributed to its high pore volume and large surface area. The pharmacokinetics of the two Cu-MOFs show that Celecoxib was fully delivered after 48 h. Molecular docking shows that celecoxib binds strongly to [Cu3(btc)2] via π–π stacking and Cu-centered interactions, while binding in [Cu3(btc)2]–ED is dominated by hydrogen bonding and aromatic contacts. The findings from this research present a novel opportunity for [Cu3(btc)2] and [Cu3(btc)2]-ED to serve as a potential platform for Celecoxib storage and stable delivery.
扫码关注我们
求助内容:
应助结果提醒方式:
